Preventative Options and the Future of Chemoprevention for Cutaneous Tumors

Published:October 27, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nemer K.M.
        • Council M.L.
        Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
        Dermatol Clin. 2019; 37: 287-295
        • Soltani-Arabshahi R.
        • Tristani-Firouzi P.
        Chemoprevention of nonmelanoma skin cancer.
        Facial Plast Surg. 2013; 29: 373-383
        • Prado R.
        • Francis S.O.
        • Mason M.N.
        • et al.
        Nonmelanoma skin cancer chemoprevention.
        Dermatol Surg Off Publ Am Soc Dermatol Surg [et al]. 2011; 37: 1566-1578
        • Thompson S.C.
        • Jolley D.
        • Marks R.
        Reduction of solar keratoses by regular sunscreen use.
        N Engl J Med. 1993; 329: 1147-1151
        • Green A.
        • Williams G.
        • Neale R.
        • et al.
        Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial.
        Lancet (London, England). 1999; 354: 723-729
        • Silva ES da
        • Tavares R.
        • Paulitsch F. da S.
        • et al.
        Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis.
        Eur J Dermatol. 2018; 28: 186-201
        • Rigel D.S.
        • Taylor S.C.
        • Lim H.W.
        • et al.
        Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel.
        J Am Acad Dermatol. 2022; 86: S1-S8
        • Downs C.A.
        • DiNardo J.C.
        • Stien D.
        • et al.
        Benzophenone Accumulates over Time from the Degradation of Octocrylene in Commercial Sunscreen Products.
        Chem Res Toxicol. 2021; 34: 1046-1054
      1. Light D, Kucera K, Wu Q. Valisure Citizen Petition on Benzene in sunscreen and after-Sun care products.; 2021.

        • Yarosh D.B.
        • Rosenthal A.
        • Moy R.
        Six critical questions for DNA repair enzymes in skincare products: a review in dialog.
        Clin Cosmet Investig Dermatol. 2019; 12: 617-624
        • Cafardi J.A.
        • Elmets C.A.
        T4 endonuclease V: review and application to dermatology.
        Expert Opin Biol Ther. 2008; 8: 829-838
        • Camp W.L.
        • Turnham J.W.
        • Athar M.
        • et al.
        New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.
        Semin Cutan Med Surg. 2011; 30: 6-13
        • Snaidr V.A.
        • Damian D.L.
        • Halliday G.M.
        Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety.
        Exp Dermatol. 2019; 28: 15-22
        • Damian D.L.
        • Patterson C.R.S.
        • Stapelberg M.
        • et al.
        UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide.
        J Invest Dermatol. 2008; 128: 447-454
        • Torti D.C.
        • Christensen B.C.
        • Storm C.A.
        • et al.
        Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.
        J Am Acad Dermatol. 2011; 65: 304-312
        • Rao C.V.
        • Reddy B.S.
        NSAIDs and chemoprevention.
        Curr Cancer Drug Targets. 2004; 4: 29-42
        • Reinau D.
        • Surber C.
        • Jick S.S.
        • et al.
        Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer.
        Int J Cancer. 2015; 137: 144-153
        • Elmets C.A.
        • Ledet J.J.
        • Athar M.
        Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention.
        J Invest Dermatol. 2014; 134: 2497-2502
        • Elmets C.A.
        • Viner J.L.
        • Pentland A.P.
        • et al.
        Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
        J Natl Cancer Inst. 2010; 102: 1835-1844
        • Quiñones O.G.
        • Pierre M.B.R.
        Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
        Curr Cancer Drug Targets. 2019; 19: 5-16
        • Chaudhary S.C.
        • Singh T.
        • Kapur P.
        • et al.
        Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.
        Toxicol Appl Pharmacol. 2013; 268: 249-255
        • Otley C.C.
        • Stasko T.
        • Tope W.D.
        • et al.
        Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.
        Dermatol Surg Off Publ Am Soc Dermatol Surg [et al]. 2006; 32: 562-568
        • Siegel J.A.
        • Korgavkar K.
        • Weinstock M.A.
        Current perspective on actinic keratosis: a review.
        Br J Dermatol. 2017; 177: 350-358
        • Schauder D.M.
        • Kim J.
        • Nijhawan R.I.
        Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review.
        JAMA Dermatol. 2020; 156: 1117-1124
        • Dinulos J.
        Premalignant and malignant nonmelanoma skin tumors.
        in: Habif’s clinical Dermatology. 2021: 815-862
        • Tang J.Y.
        • Mackay-Wiggan J.M.
        • Aszterbaum M.
        • et al.
        Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
        N Engl J Med. 2012; 366: 2180-2188
        • Alberts D.S.
        • Dorr R.T.
        • Einspahr J.G.
        • et al.
        Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine.
        Cancer Epidemiol Biomarkers Prev A Publ Am Assoc Cancer Res Cosponsored By Am Soc Prev Oncol. 2000; 9: 1281-1286
        • Bailey H.H.
        • Kim K.
        • Verma A.K.
        • et al.
        A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
        Cancer Prev Res (Phila). 2010; 3: 35-47
        • Kreul S.M.
        • Havighurst T.
        • Kim K.
        • et al.
        A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.
        Cancer Prev Res (Phila). 2012; 5: 1368-1374
        • Meyskens F.L.J.
        • Gerner E.W.
        Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
        Clin Cancer Res. 1999; 5: 945-951
        • Saraei P.
        • Asadi I.
        • Kakar M.A.
        • et al.
        The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances.
        Cancer Manag Res. 2019; 11: 3295-3313
        • Adalsteinsson J.A.
        • Muzumdar S.
        • Waldman R.
        • et al.
        Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.
        J Am Acad Dermatol. 2021; 85: 56-61
        • Chang M.S.
        • Hartman R.I.
        • Xue J.
        • et al.
        Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies.
        Cancer Prev Res (Phila). 2021; 14: 77-84
        • Tseng C.-H.
        Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes.
        J Am Acad Dermatol. 2018; 78: 694-700
        • Ravishankar A.
        • Zhang T.
        • Lindgren B.R.
        • et al.
        The effect of metformin on the risk of recurrent nonmelanoma skin cancers.
        Int J Dermatol. 2020; 59: e303-e305
        • Katiyar S.K.
        • Perez A.
        • Mukhtar H.
        Green tea polyphenol treatment to human skin prevents formation of ultraviolet light B-induced pyrimidine dimers in DNA.
        Clin Cancer Res. 2000; 6: 3864-3869
        • Meeran S.M.
        • Akhtar S.
        • Katiyar S.K.
        Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation.
        J Invest Dermatol. 2009; 129: 1258-1270
        • Nahar V.K.
        • Wilkerson A.H.
        • Ghafari G.
        • et al.
        Skin cancer knowledge, attitudes, beliefs, and prevention practices among medical students: A systematic search and literature review.
        Int J Women’s Dermatology. 2018; 4: 139-149
        • Arzeno J.
        • Leavitt E.
        • Lonowski S.
        • et al.
        Current Practices for Preventative Interventions for Nonmelanoma Skin Cancers Among Dermatologic Surgeons.
        Dermatol Surg. 2021; 47: 995-997
        • Dorrell D.N.
        • Strowd L.C.
        Skin Cancer Detection Technology.
        Dermatol Clin. 2019; 37: 527-536
      2. Tirbanibulin.
        Am J Health Pharm. 2021; 78: 656-657